Abstract
Our laboratory has discovered that blood sera of healthy men and women contain low levels of anti-HMdU (Shydroxymethyl-2′-deoxyuridine, an oxidized thymidine) autoantibodies (aAbs) (1,2) However, patients with chronic inflammatory diseases exhibit elevated anti-HMdU aAb titers. Interestingly, people at high risk for cancer, those with cancer and, most importantly, those who were diagnosed with breast, colon, and rectal cancer 0.5–6 yr after donation of the blood samples we analyzed (but not those diagnosed with nonmelanoma skin cancer) had significantly elevated anti-HMdU aAb titers (4). The high aAbs in apparently healthy women at the time of blood donation persisted for several years before diagnosis (3). We recently also showed that these anti-HMdU aAb titers depend on subject’s age and menopausal status (5) Our findings pomt to anti-HMdU aAb titers as being a biomarker of a potential to develop cancer even in the absence of family risk factors, which constitute the majority of cases
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Frenkel K., Karkoszka J., Kim E, and Taioli E. (1993) Recognition of oxidized DNA bases by sera of patients with inflammatory disease. Free Rad. Biol Med 14, 483–494
Frenkel K., Karkoszka J, Glassman T, Dubin N, Toniolo P, Taioli E, Mooney L, and Kato I (1997) Serum autoantibodies recognizing 5-hydroxy-methyl-2′-deoxyuridine, an oxidized DNA base, as biomarkers of cancer risk in women Cancer Epidemiology Blomarkers and Prevention, in press.
Frenkel K, Glassman T, Karkoszka J, and Taroh E (1994) Anti-oxidized DNA base autoantibodies as a potential biomarker of high risk for the development of human breast cancer Proc. Am Assoc. Cancer Res 35, 97
Frenkel K., Karkoszka J., Glassman T, Powell J, Pero R, Tomolo P, and Tatoli E (1995) Autoantibodies that recognize oxidized DNA bases as biomarkers of cancer risk Proc Am Assoc. Cancer Res 36, 284
Djuric Z, Heilbrun L K, Simon M. S, Luongo D A, LoRusso P M, and Martino S (1996) Levels of.5-hydroxymethyl-2′-deoxyuridine in blood DNA as a marker of breast cancer risk Cancer 77, 69l–696
Djuric Z., Heilbrun L K, Reading B. A, Boomer A, Valeriote F. A, and Martino S. (1991) Effects of a low fat diet on levels of oxidative damage to DNA in human peripheral nucleated blood cells J Natl Cancer Inst 83, 766–769
Malins D C and Haimanot R (1991) Major alterations in the nucleotide structure IN DNA in cancer of the female breast Cancer Res 51, 5430–5432.
Dunham L. J (1972) Cancer in man at a site of prior benign lesion of skin or mucous membrane: a review. Cancer Res 32, 1359–1374
Weitzman S. A. and Gordon L. I. (1990) Inflammation and cancer: role of phagocyte-generated oxidants In carcinogenesis. Blood 76, 655–663
Frenkel K (1992) Carcinogen-mediated oxidant formation and oxidative DNA damage. Pharmac Ther 53, 127–166.
Breimer L H (1990) Molecular mechanisms of oxygen radical carcinogenesis and mutagenesis: the role of DNA base damage. Mol Carcinogenesis 3, 188–197.
Teebor G W, Boorstein R J, and Cadet J. (1988) The repairability of oxidative free radical mediated damage to DNA: a review. Int J Radiat. Biol 54, 13l–150
Trush M. A. and Kensler T W. (1991) An overview of the relationship between oxidative stress and chemical carcinogenesis. Free Rad Biol Med 10, 201–209
Frenkel K., Wei L., and Wei H. (1995) 7,12-Dimethylbenz[a]anthracene Induces oxidative DNA modification In vivo. Free Rad. Biol Med 19, 373–380.
Liehr J. G and Roy D. (1990) Free radical generation by redox cycling of estrogens Free Rad Biol Med 8, 415–423.
Dipple A, Pigott M. A, Bigger A. H., and Blake D M. (1984) 7,12-Dimethyl-benz[a]anthracene-DNA binding in mouse skin: response of different mouse strains and effects of vartous modifiers of carcinogenesis. Carcinogenesis 5, 1087–1090.
McCormick D L, Major N, and Moon R C (1984) Inhibition of 7,12-dim-ethyl-benz[a]anthracene-induced rat mammary carcinogenesis by concomitant or postcarcinogen antioxidant exposure Cancer Res 44, 2858–2863
Wattenberg L W (1980) Inhibition of chemical carcinogenesis by antioxidants, in tiCarcinogenesis, Vol 5, Modifiers of Chemical Carcinogenesis (Slaga T J, ed), Raven Press, New York, pp 85–98
Perchellet J.-P and Perchellet E M (1989) Antioxidants and multistage carcinogenesis in mouse skin. Free Rad Biol Med 7, 377–408
Wet H. and Frenkel K. (1993) Relationship of oxidative events and DNA oxidation in SENCAR mice to in vivo promoting activity of phorbol ester-type tumor promoters. Carcinogenesis 14, 1195–1201.
Bhimani R. S, Troll W, Grunberger D, and Frenkel K (1993) Inhibition of oxidative stress in HeLa cells by chemopreventive agents Cancer Res 53, 4528–4533
Frenkel K, Wet H, Bhimani R, Ye J., Zadunaisky J A, Huang M-T, Ferraro T., Conney A. H, and Grunberger D. (1993) Inhibition of tumor promoter-mediated processes in mouse skin and bovine lens by caffeic acid phenethyl ester Cancer Res 53, 1255–1261.
Huang M-T, Ma W, Yen P, Xie J-Q., Han J, Frenkel K, Grunberger D, and Conney A H (1996) Inhibitory effects of caffeic acid phenethyl ester (CAPE) on 12-O-tetradecanoyl-phorbol-13-acetate-induced tumor promotion in mouse skin and the synthesis of DNA, RNA and protein in HeLa cells Carcinogenesis 17, 761–765
Wet H and Frenkel K (1992) Suppression of tumor promoter-induced oxidative events and DNA damage in vivo by sarcophytol A a possible mechanism of anti-promotion. Cancer Res 52, 2298–2303
Bhimani R. S, Zhong Z., Schleifer E, Troll W, and Frenkel K (1995) Human promyelocytic leukemia cells (HL-60), a new model to study the effects of chemopreventive agents on H2O2 production Cancer Detect Prev 9, 292–298
Lim J. S, Frenkel K, and Troll W (1992) Tamoxifen suppresses tumor promoter-induced hydrogen peroxide formation by human neutrophils Cancer Res 52, 4969–4972
Frenkel K, Chrzan K, Ryan C A, Wiesner R, and Troll W (1987) Chymot-rypsin-specific protease inhibitors decrease H2O2 formation by activated human polymorphonuclear leucocytes. Carcinogenesis 8, 1207–1212
Frenkel K., Karkoszka J, Cohen B, Baranski B., Jakubowski M., Cosma G, Taioli E., and Toniolo P. (1994) Occupational exposures to Cd, N1 and Cr modulate titers of anti-oxidized DNA base autoantibodies. Environ Health Perspect 102(Suppl. 3), 221–225
Frenkel K. (1996) U S. Patent No 5,552,285 Immunoassays methods, compositions and kits for antibodies to oxidized DNA bases
Tatoli E, Kinney P, Zhitkovich A., Fulton H, Voitkun V, Cosma G, Frenkel K, Tomolo P, Garte S, and Costa M. (1994) Application of rehabtlity models to studies of biomarker validation Environ Health Perspect 102, 306–309
Erlanger B F. and Beiser S M. (1964) Antibodies specific for ribonucleosides and ribonucleotides and their reaction with DNA Proc Natl Acad Sci USA 52, 68–74
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Humana Press Inc, Totowa, NJ
About this protocol
Cite this protocol
Frenkel, K., Karkoszka, J. (1998). Anti-HMdU Autoantibodies in Human Sera as a Biomarker of Cancer Risk. In: Hanausek, M., Walaszek, Z. (eds) Tumor Marker Protocols. Methods in Molecular Medicine™, vol 14. Springer, Totowa, NJ. https://doi.org/10.1385/0-89603-380-5:431
Download citation
DOI: https://doi.org/10.1385/0-89603-380-5:431
Publisher Name: Springer, Totowa, NJ
Print ISBN: 978-0-89603-380-1
Online ISBN: 978-1-59259-598-3
eBook Packages: Springer Protocols